About: Bosutinib Inhibits EGFR Activation in Head and Neck Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bosutinib Inhibits EGFR Activation in Head and Neck Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 21 June 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2018 (uk) im Juni 2018 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 21 June 2018 (en) artículu científicu espublizáu en xunu de 2018 (ast)
publication date	wds:Q63884105-E0F7544A-B3D7-4E29-82A1-2450989F7F22
publication date	2018-06-21 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q63884105-DED2CAE8-A423-4504-9CEC-08E23A99D917
language of work or name	English
cites work	wds:Q63884105-00DFCA44-7B37-4640-B409-1F22C297211C wds:Q63884105-117B3314-6D3D-424C-9F8D-2C057143B385 wds:Q63884105-19DABE4F-B012-4258-85F2-962A2431AA33 wds:Q63884105-236908AA-6625-478D-931E-67177363A083 wds:Q63884105-2E9D319C-9DF8-4D63-881A-6E523E983402 wds:Q63884105-4B12FFBF-BACE-4CAE-8B33-E4BE711A8921 wds:Q63884105-4ECAC62B-326A-40A5-B7F6-D80D94E6950E wds:Q63884105-4ED843DA-C802-4682-9F3B-270888C47E61 wds:Q63884105-53B11505-659D-4CD1-9115-B9BA727CCBCA wds:Q63884105-587529BC-CF51-4DBB-8E98-5B67CFD9D0B0 wds:Q63884105-61B2225B-E6D0-4C17-B5C7-2BCD65AB50C2 wds:Q63884105-6424BE9C-A008-4A77-A8E8-BBAD442876CF wds:Q63884105-65D7F5A1-9E86-469B-AB2B-30D9831758EF wds:Q63884105-6BDC7F58-832E-48AD-BE52-2EF5ED264A8E wds:Q63884105-6C349089-5B68-4FD6-B414-101504B3FE14 wds:Q63884105-6C567B91-46D6-4A7B-BDEE-CEFB6ADB3FB3 wds:Q63884105-6CE872C2-6B3D-424A-883E-79B7800B8BA3 wds:Q63884105-752468B1-D3EF-45BA-A34D-DC0ED64518A4 wds:Q63884105-805E957C-3104-4DB8-9A8C-6A541EA75738 wds:Q63884105-8983D811-9EFD-43AB-9468-D401EE569B5A wds:Q63884105-8BF16070-1CD3-4AF5-A05B-9B3D79B2B5E4 wds:Q63884105-95FDB136-2181-4162-AC55-4BD3E3AF6015 wds:Q63884105-9C4CE4BE-6B99-4975-B3E0-2CD24A6DD6EA wds:Q63884105-B8B65CAC-B3AF-48B8-9679-84881E15D2BE wds:Q63884105-BA22D6DE-6CFD-423D-8E59-46C0B1A6559B wds:Q63884105-C6B93DA1-B7BF-49B1-ACA9-F80E5749695A wds:Q63884105-C795F152-F627-43E6-AADE-A203ADE79583 wds:Q63884105-D66C2760-8974-43A9-893D-76CB241E0DD4 wds:Q63884105-E95C2256-EE19-4AFF-B32A-5D7C6D8E4F9B wds:Q63884105-EF42363C-B6C7-42F8-AA1D-92CABB6D32DF wds:Q63884105-F1F364B4-5E62-483E-AFD5-694A00A15EE8
cites work	Mechanism of biological synergy between cellular Src and epidermal growth factor receptor Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models Comprehensive genomic characterization of head and neck squamous cell carcinomas The molecular biology of head and neck cancer Discovery and saturation analysis of cancer genes across 21 tumour types Systematic identification of genomic markers of drug sensitivity in cancer cells Determination of subcutaneous tumor size in athymic (nude) mice AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials The mutational landscape of head and neck squamous cell carcinoma Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck Platinum-based chemotherapy plus cetuximab in head and neck cancer Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy Cellular functions regulated by phosphorylation of EGFR on Tyr845. Emerging drugs to treat squamous cell carcinomas of the head and neck The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature Resistance to EGFR-targeted therapy: a family affair Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. Src as a Therapeutic Target in Biliary Tract Cancer Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines. DeSigN: connecting gene expression with therapeutics for drug repurposing and development Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia
author name string	wds:Q63884105-0B211C00-A4BC-4A27-9C06-04596794E34D wds:Q63884105-A72B326E-C9A9-4E18-A1BF-27D27E2EE8E3 wds:Q63884105-E598577E-349A-4DBC-9ABD-BBC687A71B47
author name string	Carmen Segrelles David Contreras Carmen Gutiérrez-Muñoz
rdfs:label	Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (en) Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (nl)
skos:prefLabel	Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (en) Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (nl)
name	Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (en) Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (nl)
author	wds:Q63884105-7C1D99C3-726F-4B02-9A30-F23490B550CF wds:Q63884105-94F53614-672E-48D7-9EF2-0EFF1D0236C5 wds:Q63884105-CF43E027-05FC-468A-BF3E-59F78AF3B97D wds:Q63884105-D7CA0BDB-5E8A-4484-BFD8-31825BB8C0CD
author	Jesus M. Paramio Ramón García-Escudero Corina Lorz Elena M Navarro
title	wds:Q63884105-776BFD1B-485B-4AC1-8D55-FE5B626A0B8E
title	Bosutinib Inhibits EGFR Activation in Head and Neck Cancer (en)
page(s)	wds:Q63884105-EDE23E65-D109-41E4-9005-1BA44397B509
page(s)	1824
instance of	wds:Q63884105-B5B5CC5E-690A-4237-8776-084C41BC9505
instance of	scholarly article
main subject	wds:Q63884105-04313EBC-6B88-46BA-A32A-6928A192439E wds:Q63884105-170D7ACB-CEA3-4687-AAC8-3EBF26BA7E06

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software